1-(2-oxo-2-p-tolyl-ethyl)-pyridinium | 38377-67-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-oxo-2-p-tolyl-ethyl)-pyridinium
• 英文别名: N-(p-Methylphenacyl)-pyridinium；N-(p-Methylphenacyl)pyridinium；1-(4-Methylphenacyl)pyridinium；1-(4-methylphenyl)-2-pyridin-1-ium-1-ylethanone
• CAS: 38377-67-2
• 化学式: C₁₄H₁₄NO
• 分子量: 212.271
• InChiKey: QHYBBPZKHBFQKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  21
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-oxo-2-p-tolyl-ethyl)-pyridinium 、 丙烯酸乙酯 在 氧气 、 sodium acetate 、 copper(II) acetate monohydrate 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以85%的产率得到ethyl 3-(4-methylbenzoyl)indolizine-1-carboxylate
  参考文献：
  名称：

  一种吡咯并氮桥芳香化合物及其制备方法

  摘要：

  本发明公开了一种吡咯并氮桥芳香化合物及其制备方法。该化合物通过将吡啶类化合物Ⅱ与丙烯酸乙酯或丙烯酸甲酯加入到溶剂中，再加入催化剂和碱，于氧气氛围下进行反应后得到。本发明的制备方法种所涉及到的反应原料、溶剂均为市售产品，价格低廉；反应条件温和(室温即可反应)，收率良好，而且吡咯并氮桥芳香化合物产品的收率为68%‑87%，具备工业化应用前景。

  公开号：

  CN110606849A

文献信息

• [EN] NANOSCALE METAL-ORGANIC LAYERS AND METAL-ORGANIC NANOPLATES FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF<br/>[FR] COUCHES ORGANOMÉTALLIQUES NANOMÉTRIQUES ET NANOPLAQUES ORGANOMÉTALLIQUES POUR THÉRAPIE PHOTODYNAMIQUE INDUITE PAR RAYONS X, RADIOTHÉRAPIE, THÉRAPIE RODIODYNAMIQUE, CHIMIOTHÉRAPIE, IMMUNOTHÉRAPIE, ET TOUTE COMBINAISON DE CELLES-CI
  申请人：UNIV CHICAGO

  公开号：WO2019028250A1

  公开（公告）日：2019-02-07

  Metal-organic layers (MOLs) and metal-organic nanoplates (MOPs) comprising photosensitizers are described. The MOLs and MOPs can also include moieties capable of absorbing X-rays or other ionizing irradiation energy and/or scintillation. Optionally, the photosensitizer or a derivative thereof can form a bridging ligand of the MOL or MOP. Also described are methods of using MOLs and MOPs in photodynamic therapy, X-ray induced photodynamic therapy (X-PDT), radiotherapy (RT), radiodynamic therapy, or in radiotherapy-radiodynamic therapy (RT-RDT), either with or without the co-administration of another therapeutic agent, such as a chemotherapeutic agent or an immunomodulator.

  金属有机层(MOLs)和金属有机纳米片(MOPs)，包括光敏剂。MOLs和MOPs还可以包括能够吸收X射线或其他电离辐射能量和/或闪烁的基团。可选地，光敏剂或其衍生物可以形成MOL或MOP的桥联配体。还描述了在光动力疗法、X射线诱导光动力疗法(X-PDT)、放射疗法(RT)、放射动力疗法或在放射疗法-放射动力疗法(RT-RDT)中使用MOLs和MOPs的方法，无论是否与另一种治疗剂，如化疗剂或免疫调节剂的联合给药。
• Method for treating fibrotic diseases or other indications IIIC
  申请人：——

  公开号：US20020183365A1

  公开（公告）日：2002-12-05

  Provided is a method of treating or ameliorating certain fibrotic diseases or other indications in an animal, including a human, comprising administering an effective amount of a compound of the formula I: Y—Ar⊕·X — wherein: a. Ar is a five or six membered heteroaryl ring having a first ring nitrogen and optionally second or third ring nitrogens, with the remaining ring atoms being carbon, oxygen, or sulfur, provided the first nitrogen of Ar is a quaternary nitrogen and Ar is not thiazolium, oxazolium or imidazolium; b. Y is substituted on the first ring nitrogen, with the proviso that if Ar is pyrazole, indazole, (1,2,3)-triazole, benzotriazole, or (1,2,4)-triazole, the second ring nitrogen is substituted C. Y is: 1 . a group of the formula —CH(R 5 )—R 6 [as preferred in one embodiment] (a) wherein R 5 is hydrogen, alkyl, cycloalkyl-, alkenyl-, alkynyl-, aminoalkyl-, hydroxy[C 1 to C 6 ]alkyl, dialkylaminoalkyl-, (N-[C 6 or C 10 ]aryl)(N-alkyl)aminoalkyl-, piperidin-1-ylalkyl-, pyrrolidin-1-ylalkyl, azetidinylalkyl, 4-alkylpiperazin-1-ylalkyl, 4-alkylpiperidin-1-ylalkyl, 4-[C 6 or C 10 ]arylpiperazin-1-ylalkyl, 4-[C 6 or C 10 ]arylpiperidin-1-ylalkyl, azetidin-1-ylalkyl, morpholin-4-ylallcyl, thiomorpholin-4-ylalkyl, piperazin-1-ylalkyl, piperidin-1-ylalkyl, [C 6 or C 10 ]aryl, or independently the same as R 6 ; (b) wherein R 6 is (1) hydrogen, alkyl (which may be substituted by alkoxycarbonyl)-, alkenyl, alkynyl, cyano-, cyanoalkyl-, or Rs, wherein Rs is a [C 6 or C 10 ]aryl or a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur; or (2) a group of the formula —W—R 7 [as preferred in one embodiment], wherein R 7 is alkyl, alkoxy, hydroxy, or Rs [as preferred in one embodiment], wherein W is —C(═O)— or —S(O) 2 —; (3) a group of the formula —W—OR 8 wherein R 8 is hydrogen or alkyl, (4) a group of the formula —CH(OH)Rs; or (5) a group of the formula —W—N(R 9 )R 10 , wherein (a) R 9 is hydrogen and R 10 is an alkyl or cycloalkyl, optionally substituted; or (b) R 9 is hydrogen or alkyl and R 10 is Ar; or (c) R 9 is hydrogen or alkyl, R 10 is a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms are selected from the group consisting of oxygen, nitrogen and sulfur; or (d) R 9 and R 10 are both alkyl groups; or (e) R 9 and R 10 together with N form a heterocycle containing 4-10 ring atoms which can incorporate up to one additional heteroatom selected from the group of N, O or S in the ring, wherein the heterocycle is optionally substituted; or (f) R 9 and R 10 are both hydrogen; or 2 . —NH 2 , and e. X is a pharmaceutically acceptable anion, which may be absent if the compound provides a neutralizing salt, or (B) a pharmaceutically acceptable salt of the compound.

  提供一种治疗或改善动物中的某些纤维化疾病或其他适应症的方法，包括人类，包括给予化合物I的有效量：Y—Ar⊕·X—其中：a. Ar是一个具有第一个环氮原子和可选择第二或第三环氮原子的五元或六元杂环芳基环，其余环原子为碳、氧或硫，前提是Ar的第一个氮原子是季铵氮，且Ar不是噻唑、噁唑或咪唑；b. Y取代在第一个环氮原子上，但前提是如果Ar是吡唑、吲唑、(1,2,3)-三唑、苯并三唑或(1,2,4)-三唑，则第二环氮原子被取代；c. Y是：1. 公式为—CH(R5)—R6[在一个实施例中优选]的基团(a)其中R5是氢、烷基、环烷基、烯基、炔基、氨基烷基、羟基[C1到C6]烷基、二烷基氨基烷基、(N-[C6或C10]芳基)(N-烷基)氨基烷基、哌啶-1-基烷基、吡咯啉-1-基烷基、氮杂环烷基、4-烷基哌嗪-1-基烷基、4-烷基哌啶-1-基烷基、4-[C6或C10]芳基哌嗪-1-基烷基、4-[C6或C10]芳基哌啶-1-基烷基、氮杂环烷基、吗啉-4-基烷基、硫代吗啉-4-基烷基、哌嗪-1-基烷基、哌啶-1-基烷基、[C6或C10]芳基，或独立地与R6相同；(b)其中R6是(1)氢、烷基(可由烷氧羰基取代)-、烯基、炔基、氰基、氰基烷基、或Rs，其中Rs是一个[C6或C10]芳基或含有1-3个杂原子（氧、氮和硫）的4-10个环原子的杂环；或(2) 公式为—W—R7[在一个实施例中优选]，其中R7是烷基、烷氧基、羟基或Rs [在一个实施例中优选]，其中W是—C(═O)—或—S(O)2—；(3) 公式为—W—OR8，其中R8是氢或烷基，(4) 公式为—CH(OH)Rs；或(5) 公式为—W—N(R9)R10，其中(a) R9是氢，R10是烷基或环烷基，可选择取代；或(b) R9是氢或烷基，R10是Ar；或(c) R9是氢或烷基，R10是含有1-3个杂原子（氧、氮和硫）的4-10个环原子的杂环；或(d) R9和R10都是烷基基团；或(e) R9和R10连同N形成含有4-10个环原子的杂环，该环可在环中包含最多一个额外的来自N、O或S的杂原子，该杂环可选择取代；或(f) R9和R10都是氢；或2. —NH2，e. X是一种药用可接受的阴离子，如果化合物提供中和盐，则可能不存在，或(B) 化合物的药用可接受的盐。
• Apoptosis Inhibitors
  申请人：Carson Dennis A.

  公开号：US20080280903A1

  公开（公告）日：2008-11-13

  The present invention provides compounds that act as selective agents to protect against unintentional cell death or tissue damage and can relieve side effects of cancer treatment such as, for example, oral mucositis, hair loss, diarrhea due to damage to the gastrointestinal epithelium, and myelosuppression. In addition, these compounds can be used to prevent premature cell death when the cell death is caused by signals from damaged cells, for example, signals generated as the result of a traumatic incident or an ischemic episode.

  本发明提供了一种化合物，其作为选择性试剂，可以保护细胞免受意外死亡或组织损伤，并可以缓解癌症治疗的副作用，例如口腔黏膜炎、脱发、由于胃肠上皮损伤引起的腹泻和骨髓抑制。此外，这些化合物还可以用于预防细胞过早死亡，当细胞死亡是由于受损细胞发出的信号引起，例如创伤事件或缺血发作的结果产生的信号。
• IMAGE FORMING METHOD
  申请人：GOTOU Hiroshi

  公开号：US20130155145A1

  公开（公告）日：2013-06-20

  An image forming method applying a pretreatment liquid on the surface of a recording medium; and applying an inkjet ink including a colorant, a hydrosoluble organic solvent, a surfactant and water on the surface applied with the pretreatment liquid, wherein the hydrosoluble organic solvent includes at least one polyol including an equilibrium water content in an amount not less than 30% by weight at 23° C. and 80% RH; an amide compound having the following formula (I); and at least one of compounds having the following formulae (II) to (IV), and wherein a pure water transfers to the recording medium in an amount of from 1 to 15 mL/m 2 when measured by a dynamic scanning liquid absorptometer at a contact time of 100 ms.

  一种图像形成方法，其在记录介质的表面上应用预处理液，并在应用预处理液的表面上应用包括颜料、水溶性有机溶剂、表面活性剂和水的喷墨墨水，其中水溶性有机溶剂包括至少一种多元醇，其在23℃和80%相对湿度下的平衡含水量不少于30%（重量百分比），具有以下式（I）的酰胺化合物，以及具有以下式（II）至（IV）之一的化合物，其中在100ms接触时间下，通过动态扫描液体吸收计测量，纯水向记录介质转移的量为1至15 mL/m2。
• Method for treating glaucoma IIIB
  申请人：——

  公开号：US20020156080A1

  公开（公告）日：2002-10-24

  Provided is a method of treating, ameliorating or preventing certain fibrotic diseases or other indications in an animal, including a human, comprising administering an intraocular pressure decreasing or accommodation improving amount of (A) a compound of formula (I): Y—Ar ⊕ .X − (I)

  本发明提供了一种治疗、改善或预防动物（包括人类）的某些纤维化疾病或其他适应症的方法，该方法包括施用一定量的降低眼压或改善适应性的(A)式(I)化合物： Y-Ar ⊕ .X - (I)